A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With REGN2810 in Patients With Relapsed/Refractory Multiple Myeloma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Oct 2017
At a glance
- Drugs Cemiplimab (Primary) ; Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 16 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 12 Jan 2018.
- 16 Oct 2017 Status changed from recruiting to not yet recruiting.
- 18 Sep 2017 Planned End Date changed from 8 Oct 2019 to 26 Feb 2020.